8-K: NeuroBo Pharmaceuticals Appoints Marshall Woodworth as Chief Financial Officer

NeuroBo Pharmaceuticals has appointed Marshall Woodworth as its Chief Financial Officer, effective March 1, 2024, after he served as acting CFO since October 2023.

Summary

• NeuroBo Pharmaceuticals has officially appointed Marshall H. Woodworth as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective March 1, 2024.
• Mr. Woodworth previously served as the company's Acting Chief Financial Officer from October 27, 2023, to February 29, 2024, through an agreement with WhiteCap Search Holdings, LLC.
• The company terminated its engagement agreement with WhiteCap Search Holdings, LLC upon Mr. Woodworth's official appointment.
• Mr. Woodworth's employment agreement has an initial term of two years, automatically renewing for one-year periods unless the board provides 60 days' notice of non-renewal.
• He will receive an annual base salary of $380,000, subject to annual review, and is eligible for an annual incentive bonus targeted at 40% of his base salary.
• Mr. Woodworth was granted a restricted stock unit award for 33,496 shares, vesting over three years with 30% on the first and second anniversaries and the remainder in equal monthly installments over the following 12 months.
• The agreement includes severance provisions, including 25% of his annual base salary and three months of COBRA coverage, under certain termination conditions.
• In the event of a change of control, unvested stock options will fully vest if not assumed by the acquiring company.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CFO and the company's progress in clinical trials. The terms of the employment agreement are also favorable.

Positives

• The appointment of a permanent CFO provides stability and continuity to the company's financial leadership.
• Mr. Woodworth has extensive experience as a CFO in the pharmaceutical and medical device industries.
• The employment agreement includes a competitive base salary and bonus structure.
• The vesting schedule of the restricted stock units incentivizes long-term commitment.
• The severance package provides a safety net for Mr. Woodworth in case of termination under certain conditions.
• The accelerated vesting of equity awards in a change of control scenario is beneficial for Mr. Woodworth.

Negatives

• The company terminated its agreement with WhiteCap Search Holdings, LLC, which may have associated costs.
• The severance package is not triggered in all termination scenarios, such as termination for cause or resignation without good reason.

Risks

• The company's financial performance could be impacted if Mr. Woodworth does not perform as expected.
• The company may face challenges in retaining Mr. Woodworth if the employment terms are not competitive.
• The company's stock price could be negatively affected if the market perceives the appointment or the terms of the agreement unfavorably.
• There is a risk of potential legal disputes if the terms of the employment agreement are not clearly defined or if there are disagreements over termination conditions.

Future Outlook

The company anticipates reporting full data from the Phase 2a clinical trial for DA-1241 in the second half of the year and initiating a Phase 1 clinical trial for DA-1726 in the first half of the year.

Management Comments

• Hyung Heon Kim, President and CEO, stated that Mr. Woodworth's experience makes him an obvious choice for the permanent CFO role.
• Mr. Kim expressed confidence that Mr. Woodworth will play a pivotal role in the company's success.
• Mr. Woodworth stated he looks forward to continuing his role on NeuroBo's executive team and advancing clinical milestones.

Industry Context

This announcement is consistent with the need for biotech companies to secure experienced financial leadership as they progress through clinical trials and seek to commercialize their products. The appointment of a seasoned CFO like Mr. Woodworth is a positive signal for investors.

Comparison to Industry Standards

• The base salary of $380,000 is within the typical range for CFOs at clinical-stage biotech companies of similar size and stage.
• The 40% target bonus is also a common incentive structure in the biotech industry.
• The vesting schedule for the restricted stock units is standard practice for executive compensation.
• The severance package is comparable to those offered to other executives in similar roles.
• Companies such as Madrigal Pharmaceuticals, Viking Therapeutics, and Intercept Pharmaceuticals, which are also focused on MASH and cardiometabolic diseases, have similar compensation structures for their executive teams.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a permanent CFO as a positive development, potentially increasing investor confidence.
• Employees may benefit from the stability and leadership provided by a permanent CFO.
• Customers and partners may gain confidence in the company's financial stability and long-term prospects.
• Creditors may view the appointment as a sign of financial responsibility and stability.

Next Steps

• Mr. Woodworth will assume his responsibilities as CFO, Principal Financial Officer, and Principal Accounting Officer.
• The company will continue to advance the clinical development of DA-1241 and DA-1726.
• The company will report full data from the Phase 2a clinical trial for DA-1241 in the second half of the year.
• The company will initiate a Phase 1 clinical trial for DA-1726 in the first half of the year.

Key Dates

Keywords

Chief Financial Officer, CFO, executive appointment, employment agreement, restricted stock units, severance, NeuroBo Pharmaceuticals, financial officer, biotechnology, MASH, obesity, clinical trials